ArticleItalian journal of pediatrics2025
Prediction model for severe mycoplasma pneumoniae pneumonia and analysis of macrolide-resistance in children: a case-control study.
Article in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Machine learning-based prediction models for severeFrontiers in public health · 2026Pooled it
- Association between point mutations of macrolide-resistantFrontiers in pharmacology · 2025Pooled it
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Machine learning-driven risk assessment of severeFrontiers in medicine · 2026Article
- Analysis of Clinical Characteristics and Risk Factors of Pediatric Macrolide-ResistantInfection and drug resistance · 2026Article
- A Novel Nomogram Integrating Clinical, Radiological, and Immunological Indicators for Early Prediction of SevereJournal of inflammation research · 2026Article
- Construction of a nomogram combining CT and serum markers for predicting macrolide resistance gene mutation status in pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- AgeFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo analyze the clinical features, laboratory findings, and imaging characteristics of severe Mycoplasma pneumoniae pneumonia (SMPP) in children, identify early warning indicators, and characterize macrolide-resistant M. pneumoniae pneumonia (MRMPP). Additionally, we developed and validated a nomogram model for predicting the risk of SMPP.
methodsThis retrospective cohort study included children diagnosed with M. pneumoniae pneumonia (MPP) who were admitted to the West China Second Hospital of Sichuan University between September 2022 and February 2024. Data on demographics, clinical manifestations, laboratory results, and imaging findings were collected and analyzed.
resultsCompared to non-severe cases, children with SMPP had a significantly longer fever duration (8 days vs. 4 days, P < 0.001), higher peak body temperature (39.3 °C vs. 38.5 °C, P < 0.001), and a higher incidence of wheezing (13% vs. 0%, P < 0.05). There was no significant difference in macrolide resistance rates between the groups (P > 0.05). Radiological analysis revealed a higher frequency of pulmonary consolidation (69% vs. 0%, P < 0.001) and pleural effusion (22% vs. 7%, P = 0.031) in the SMPP cohort. LASSO regression identified eight key predictors: fever duration, peak body temperature, wheezing, extrapulmonary complications, hemoglobin levels, pulmonary consolidation, mosaic sign, and bronchial occlusion. The nomogram demonstrated excellent discriminative ability, with training and validation AUC values of 0.972 (95% CI 0.960-0.984) and 0.975 (95% CI 0.958-0.992), respectively.
conclusionsWe developed and validated a nomogram for quantitative risk assessment of SMPP. This model can aid clinicians in the early identification of severe cases and in optimizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.